{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:26Z","timestamp":1761863426876},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T00:00:00Z","timestamp":1432598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0127832","type":"journal-article","created":{"date-parts":[[2015,5,26]],"date-time":"2015-05-26T18:21:54Z","timestamp":1432664514000},"page":"e0127832","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials"],"prefix":"10.1371","volume":"10","author":[{"given":"Anthony A.","family":"Bavry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam Y.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj P.","family":"Jadhav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyao","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,5,26]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.jacc.2010.10.030","article-title":"Efficacy and safety of glycoprotein IIb\/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines","volume":"57","author":"DE Winchester","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial","volume":"289","author":"AM Lincoff","year":"2003","journal-title":"JAMA"},{"key":"ref3","first-page":"e44","article-title":"2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions","volume":"58","author":"GN Levine","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/eurheartj\/ehq277","article-title":"Guidelines on myocardial revascularization","volume":"31","author":"W Wijns","year":"2010","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(14)61216-2","article-title":"Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials","volume":"384","author":"MA Cavender","year":"2014","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.amjcard.2014.04.033","article-title":"Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction","volume":"114","author":"R Nairooz","year":"2014","journal-title":"Am J Cardiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jacc.2005.12.077","article-title":"A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial","volume":"47","author":"CM Gibson","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1056\/NEJMoa1109596","article-title":"Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction","volume":"365","author":"A Kastrati","year":"2011","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"GW Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1067\/mhj.2002.122173","article-title":"Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET)","volume":"143","author":"AM Lincoff","year":"2002","journal-title":"Am Heart J"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.amjcard.2009.06.035","article-title":"Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention","volume":"104","author":"D Tavano","year":"2009","journal-title":"Am J Cardiol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehu182","article-title":"Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction","volume":"35","author":"S Schulz","year":"2014","journal-title":"Eur Heart J"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"GW Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1067\/mhj.2002.120405","article-title":"Bivalirudin as a replacement for unfractionated heparin in unstable angina\/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction","volume":"143","author":"EM Antman","year":"2002","journal-title":"Am Heart J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199509213331204","article-title":"Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators","volume":"333","author":"JA Bittl","year":"1995","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.CIR.91.8.2132","article-title":"Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction","volume":"91","author":"P Theroux","year":"1995","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.87.5.1622","article-title":"Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty","volume":"87","author":"EJ Topol","year":"1993","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacc.2008.05.036","article-title":"Safety and efficacy of bivalirudin with and without glycoprotein IIb\/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial","volume":"52","author":"HD White","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mhj.2001.119374","article-title":"Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study","volume":"142","author":"JA Bittl","year":"2001","journal-title":"Am Heart J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"GW Stone","year":"2011","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.amjcard.2007.02.106","article-title":"Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin","volume":"100","author":"SX Anand","year":"2007","journal-title":"Am J Cardiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1067\/mhj.2002.120297","article-title":"Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb\/IIIa antagonist eptifibatide","volume":"143","author":"NS Kleiman","year":"2002","journal-title":"Am Heart J"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1160\/TH05-10-0700","article-title":"Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study","volume":"95","author":"EI Lev","year":"2006","journal-title":"Thromb Haemost"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/ATVBAHA.107.144576","article-title":"Effects of unfractionated heparin and glycoprotein IIb\/IIIa antagonists versus bivalirdin on myeloperoxidase release from neutrophils","volume":"27","author":"G Li","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.amjcard.2005.02.012","article-title":"Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study)","volume":"95","author":"JF Saucedo","year":"2005","journal-title":"Am J Cardiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/eurheartj\/ehn195","article-title":"Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention","volume":"29","author":"D Sibbing","year":"2008","journal-title":"Eur Heart J"},{"key":"ref27","first-page":"611","article-title":"The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results","volume":"15","author":"KW Mahaffey","year":"2003","journal-title":"J Invasive Cardiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1093\/eurheartj\/ehq330","article-title":"ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention","volume":"31","author":"S Schulz","year":"2010","journal-title":"Eur Heart J"},{"key":"ref29","first-page":"15","article-title":"Presented at ACC","author":"M Valgimigli","year":"2015"},{"key":"ref30","article-title":"Bivalirudin vs. heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial","author":"Y Han","year":"2015","journal-title":"JAMA"},{"key":"ref31","first-page":"414","article-title":"Novel approaches for preventing or limiting events (NAPLES) III Trial. Randomised comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting","volume":"8","author":"C Briguori","year":"2015","journal-title":"JACC Cardiovasc Intervent"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0034-1372244","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients at high risk for bleeding","volume":"23","author":"A Feldman","year":"2014","journal-title":"Int J Angiol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"A Shahzad","year":"2014","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/eurheartj\/ehu214","article-title":"Bivalirudin is superior to heparins alone with bailout GP IIb\/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial","volume":"35","author":"U Zeymer","year":"2014","journal-title":"Eur Heart J"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.3760\/cma.j.issn.0366-6999.20122569","article-title":"Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention","volume":"126","author":"DC Xiang","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/joic.12005","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III)","volume":"26","author":"R Waksman","year":"2013","journal-title":"J Interv Cardiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.amjcard.2012.04.017","article-title":"Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study)","volume":"110","author":"G Patti","year":"2012","journal-title":"Am J Cardiol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.amjcard.2009.12.001","article-title":"Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial)","volume":"105","author":"G Parodi","year":"2010","journal-title":"Am J Cardiol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMoa0802944","article-title":"Bivalirudin versus unfractionated heparin during percutaneous coronary intervention","volume":"359","author":"A Kastrati","year":"2008","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ihj.2012.07.022","article-title":"Safety and efficacy of bivalirudin with glycoprotein IIb\/IIIa for high-risk percutaneous coronary intervention","volume":"64","author":"NV Deshpande","year":"2012","journal-title":"Indian Heart J"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ccd.22876","article-title":"A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial","volume":"77","author":"DJ Moliterno","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial","volume":"369","author":"GW Stone","year":"2007","journal-title":"Lancet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.amjcard.2004.01.033","article-title":"Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)","volume":"93","author":"AM Lincoff","year":"2004","journal-title":"Am J Cardiol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent thrombosis in randomized clinical trials of drug-eluting stents","volume":"356","author":"L Mauri","year":"2007","journal-title":"N Engl J Med"},{"key":"ref45","article-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JP Higgins","year":"2011"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"S Yusuf","year":"1985","journal-title":"Prog Cardiovasc Dis"},{"key":"ref47","first-page":"3","article-title":"Meta-analysis of safety for low event-rate binomial trials","author":"JJ Shuster","year":"2012","journal-title":"Res Synth Methods"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JP Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"RM Harbord","year":"2006","journal-title":"Stat Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"D Moher","year":"2009","journal-title":"BMJ"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"P J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"ref52","first-page":"20140729e","article-title":"Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials","author":"S Cassese","year":"2014","journal-title":"EuroIntervention"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa1311096","article-title":"EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI","volume":"369","author":"PG Steg","year":"2013","journal-title":"N Engl J Med"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.amjcard.2012.03.051","article-title":"Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention","volume":"110","author":"OF Bertrand","year":"2012","journal-title":"Am J Cardiol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/eurheartj\/ehp186","article-title":"Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin","volume":"30","author":"RB Eslam","year":"2009","journal-title":"Eur Heart J"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","article-title":"Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature","volume":"53","author":"JA Sterne","year":"2000","journal-title":"J Clin Epidemiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0127832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T06:29:42Z","timestamp":1717914582000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0127832"}},"subtitle":[],"editor":[{"given":"Kevin J.","family":"Croce","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,5,26]]},"references-count":56,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2015,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0127832","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,26]]}}}